References
- 홍영표. 우리 나라 결핵–어제, 오늘, 내일. 결핵 및 호흡기질환 1997;44:1-10
- Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis 2003;7:912-9
- Espinal MA, Laszlo A, Simonsen L, Bou lahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Uni on against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001;344:1294-303
- American Thoracic Society/Centers for Di sease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359–74
- American Thoracic Society/Centers for Disease Control andPrevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–62
- British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48
- 대한결핵 및 호흡기학회. 폐결핵 진료의 기준, 1997. 결핵 및 호흡기질환 1997;44:1447-53
- 국립보건원. 2002년 결핵관리지침. 서울: 국립 보건원; 2002
- 김경찬, 고원중, 권오정, 서지영, 정만표, 김호중 등. 한 민간종합병원에서 진단된 폐결핵 환자의 약제내성 실태조사. 결핵 및 호흡기질환 2003;55(Suppl 2):83. (abstract)
- American Thoracic Society. Diagnostic stan dards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95
- Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997;1:302-8
- World Health Organization, International Uni on Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuber culosis control. Int J Tuberc Lung Dis 2001;5:213-5
- World Health Organization. Treatment of tuberculosis: guidelines for national program mes. 3rd ed. Geneva, Switzerland, World Health Organization, 2003
- World Health Organization. Guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland, World Health Organi zation, 1997
- Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-45
- Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis 1981;123:262-4
- Harkin TJ, Condos R. Chapter 48. Manage ment of multidrug-resistant tuberculosis. In: Rom WN, Garay SM, editors. Tuberculosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 729-38
- Mitchison DA, Nunn AJ. Influence of initialdrug resistance on the response to shortcourse chemotherapy of pulmonary tuber culosis. Am Rev Respir Dis 1986;133:423-30
- Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuber culosis units, 1946-1986, with relevant sub sequent publications. Int J Tuberc Lung Dis 1999;3(Suppl 2):S231-79
- Singapore Tuberculosis Service/British Medi cal Research Council. Clinical trial of sixmonth and four-month regimens of chemo therapy in the treatment of pulmonary tuber culosis. Am Rev Respir Dis 1979;119:579-85
- Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuber culosis. Lancet 1981;1:171-4
- Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987;136:1339-42
- Nolan CM, Goldberg SV. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis 2002;6:952-8
- Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 2001;119:1730-6
- Tenover FC, Crawford JT, Huebner RE, Geiter LJ, Horsburgh CR Jr, Good RC. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol. 1993;31:767-70
- 김미나, 이선화, 양성은, 배직현. 국내 3차 및 대학병원에서의 결핵균 검사 실태조사. 대한임상병리학회지 1999;19:86-91
- 장철훈, 박태성, 김미나, 이남용, 이희주, 서진태. 국내 결핵균 검사 기관의 결핵균 검사 실태의변화. 대한임상미생물학회지 2001;4:108-14
- 배직현. 우리나라 결핵균 검사의 현재와 미래: 얼마나 빠르게, 어디까지 해야하나? 대한임상병리학회 춘계 학술대회 초록집 1997;17(Suppl):S20-5
- 고윤석. 우리나라 결핵균 검사의 현재와 미래: 임상의의 기대. 대한임상병리학회 춘계 학술대회 초록집 1997;17(Suppl):S26-31
- Babu Swai O, Aluoch JA, Githui WA, Thiong'o R, Edwards EA, Darbyshire JH, etal. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant tuberculosis. Tubercle 1988;69:5-14
- Ormerod LP, Horsfield N, Green RM. Can a nine-month regimen be used to treat isoni azid resistant tuberculosis diagnosed after standard treatment is started? J Infect 2001;42:1-3
- 고원중, 권오정, 김철홍, 안영미, 임성용, 윤종욱 등. 한 민간종합병원에서 진단된 폐결핵 환자의 특성과 치료성적. 결핵 및 호흡기질환 2003;55:154-64
- 안석진, 박상준, 강경우, 서지영, 정만표, 김호중 등. 한국인 결핵환자에서 Isoniazid와 Rifampicin의 약동학. 결핵 및 호흡기질환 1999;47:442-50
- Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIVinfected tuberculosis patients. Chest 1998;113:1178-83
- Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;120:1520-4
- Telzak EE, Sepkowitz K, Alpert P, Man nheimer S, Medard F, el-Sadr W, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-11
- Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998;2:877-84
- Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levoflo xacin-containing regimens. Chest 2000;117:744-51